Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Average (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Equity Average data on record, last reported at $323.4 million in Q4 2025.

  • For Q4 2025, Equity Average fell 24.0% year-over-year to $323.4 million; the TTM value through Dec 2025 reached $323.4 million, down 24.0%, while the annual FY2025 figure was $367.4 million, 9.5% up from the prior year.
  • Equity Average reached $323.4 million in Q4 2025 per TRDA's latest filing, down from $360.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $426.2 million in Q3 2024 and bottomed at $218.3 million in Q2 2023.
  • Average Equity Average over 4 years is $307.1 million, with a median of $266.7 million recorded in 2022.
  • Peak YoY movement for Equity Average: skyrocketed 87.92% in 2024, then dropped 24.0% in 2025.
  • A 4-year view of Equity Average shows it stood at $222.9 million in 2022, then rose by 9.7% to $244.5 million in 2023, then surged by 74.05% to $425.6 million in 2024, then decreased by 24.0% to $323.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $323.4 million in Q4 2025, $360.1 million in Q3 2025, and $398.4 million in Q2 2025.